For decades, scientists have leaned on the idea that animal communication is more dependent on genetics than locale. A dog is not going to learn to meow just because it’s raised around cats.

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

When Conor Ireland picked up his cold brew at a Starbucks in London, Ontario, last month, he discovered a drawing of a sausage-shaped creature saying “neigh.” “Why is there a salamander ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

TOLEDO, Ohio (WTVG) - A Toledo Police officer is on restricted duty after criminal charges were filed for alleged cruelty to animals. Toledo Police announced Tuesday that Toledo Humane Society ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro (ertugliflozin) as a monotherapy in conjunction with diet and ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

After days of speculation, Merck & Co confirmed today that it has agreed to acquire Acceleron Pharma $1.5 billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far.